CHIMOTO Tadashi | Drug Safety and Disposition
スポンサーリンク
概要
関連著者
-
Sagami Fumio
第一三共安全性研究所
-
Sagami Fumio
Drug Safety Research Laboratories Eisai Co. Ltd.
-
Sagami Fumio
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Sagami Fumio
Department Of Drug Safety Research Eisai Kawashima Research Laboratories Eisai Co. Ltd.
-
AOKI Toyohiko
Drug Safety Research Laboratories, Eisai Co., Ltd.
-
Aoki Toyohiko
Global Drug Safety Eisai Co. Ltd.
-
TSUKIDATE Kazuo
Drug Safety Research Laboratories, Eisai Co., Ltd
-
SATO Gen
Drug Safety Research Laboratories
-
Sato Gen
Drug Safety And Disposition
-
Sato Gen
Drug Safety Research Laboratories Eisai Co. Ltd.
-
HOSOKAWA Satoru
Drug Safety Research Lab., Eisai Co., Ltd.
-
Tsukidate Kazuo
Global Drug Safety Eisai Co. Ltd.
-
Tsukidate Kazuo
Drug Safety Research Lab. Eisai Co. Ltd.
-
CHIMOTO Tadashi
Drug Safety and Disposition
-
Hosokawa Satoru
Drug Safety And Disposition
-
Aoki Toyohiko
Drug Safety Japan Global Drug Safety Biopharmaceutical Assessments Core Function Unit
-
Hakura Atsushi
Drug Safety Research Laboratories, Eisai Co., Ltd.
-
Hakura Atsushi
Global Drug Safety Eisai Co. Ltd.
-
Hakura Atsushi
Drug Safety Research Laboratories Eisai Co. Ltb.
-
KOBAYASHI Naoki
Discovery Technology Research Laboratories
-
SAGAMI Fumio
Medical Regulatory Affairs and Pharmacovigilance Department, Eisai Co., Ltd.
-
SUMIGAMA Shuji
Drug Safety & Disposition Research Laboratories, Eisai Co., Lid.
-
Sumigama Shuji
Drug Safety & Disposition Research Laboratories Eisai Co. Lid.
-
Sagami Fumio
Drug Safety Research Laboratories Eisai Co. Ltb.
-
Sagami Fumio
Medical Regulatory Affairs And Pharmacovigilance Department Eisai Co. Ltd.
-
Chimoto Tadash
Drug Safety & Disposition Research Laboratories, Eisai Co., Lid.
著作論文
- Mechanism for benzothiazole derivative-induced hepatotoxicity in rats(SYMPOSIUM 1 : MECHANISMS OF HEPATOTOXIC EFFECTS)
- TOXICOLOGICAL RESPONSE OF RATS TO A NOVEL MONOAMINE OXIDASE TYPE-A INHIBITOR, (5R)-3-[2-((1S)-3-CYANO-1-HYDROX-YPROPYL)BENZOTHIAZOL-6-YL]-5-METHOXYMETHYL-2-OXAZOLIDI-NONE (E2011), ORALLY ADMINISTERED FOR 13 WEEKS